The impact of ZNF217 mutation and TMB on treatment response (IMAGE)

Sichuan International Medical Exchange and Promotion Association

The impact of ZNF217 mutation and TMB on treatment response

Caption

The study found that patients with low tumor mutation burden (TMB) responded better to treatment, suggesting that TMB levels may serve as a critical factor in predicting therapeutic outcomes. Additionally, the study delved into the relationship between gene mutations and treatment responses, identifying a significant association between ZNF217 mutations and enhanced treatment efficacy. Specifically, patients with ZNF217 mutations demonstrated better clinical outcomes with the combination therapy, providing a biomarker foundation for future personalized treatment strategies. This finding further reinforces the role of precision medicine in breast cancer therapy, indicating that genetic testing could be employed to identify the most suitable patient population for combination treatment.

Credit

Ying Wang

Usage Restrictions

Please note source

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.